Forte Biosciences (FBRX) Prepaid Assets (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Prepaid Assets of $6.9 million for Q1 2026, up 428.96% year-over-year from $1.3 million in Q1 2025, and up 89.62% quarter-over-quarter from $3.6 million in Q4 2025.
Forte Biosciences (FBRX) Prepaid Assets (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Prepaid Assets for 11 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets rose 428.96% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 428.96% YoY), while the FY2025 annual figure was $3.6 million, up 1169.93% from the prior year.
- Prepaid Assets climbed to $6.9 million in Q1 2026 per FBRX's latest filing, from $3.6 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $6.9 million in Q1 2026 and bottomed at $70000.0 in Q4 2022.
- Historically, Prepaid Assets has averaged $935235.3 across 5 years, with a median of $286000.0 in 2024.
- Annual changes were most pronounced in 2022 — Prepaid Assets plunged 86.64% — and 2025, when it soared 1169.93%.
- Forte Biosciences' Prepaid Assets stood at $70000.0 in 2022, then jumped by 354.29% to $318000.0 in 2023, then decreased by 10.06% to $286000.0 in 2024, then jumped by 1169.93% to $3.6 million in 2025, then soared by 89.62% to $6.9 million in 2026.
- Business Quant data shows FBRX's Prepaid Assets at $6.9 million in Q1 2026, $3.6 million in Q4 2025, and $471000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.64 Mn |
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 3.63 Mn |
| Sep 30, 2025 | 471,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 286,000.00 |
| Sep 30, 2024 | 274,000.00 |
| Jun 30, 2024 | 214,000.00 |
| Mar 31, 2024 | 233,000.00 |
| Dec 31, 2023 | 318,000.00 |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 322,000.00 |
| Mar 31, 2023 | 260,000.00 |
| Dec 31, 2022 | 70,000.00 |
| Sep 30, 2022 | 119,000.00 |
| Jun 30, 2022 | 94,000.00 |
| Mar 31, 2022 | 287,000.00 |
| Dec 31, 2021 | 476,000.00 |
| Sep 30, 2021 | 891,000.00 |